We are live on ! Find out more
EBS icon

Emergent Biosolutions
EBS

Fund managers haven’t disclosed any holdings of EBS yet.

EBS Hedge Fund Activity: Q1 2026 in Review

190 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q1 2026, worth a combined $361M — down 33% from $537M a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new EBS positions and 26 closed out — a net gain of 11 holders — while 70 added to existing stakes and 53 trimmed.

The largest buyer was Prosight Management, opening a new position worth an estimated $6.62M. The largest seller was Oak Hill Advisors, cutting an estimated $25.9M.

  • 190 institutional investors held Emergent Biosolutions (EBS) as of Q1 2026, up from 183 in Q4 2025.
  • Funds reported $361M of Emergent Biosolutions stock for Q1 2026, down 33% quarter-over-quarter.
  • 37 funds opened new Emergent Biosolutions positions in Q1 2026 and 26 closed out, a net change of +11 holders.
  • The largest Emergent Biosolutions buyer in Q1 2026 was Prosight Management, an estimated $6.62M added.
  • The largest Emergent Biosolutions seller in Q1 2026 was Oak Hill Advisors, an estimated $25.9M sold.

Based on aggregated 13F filings for Q1 2026.